GLPG Company Profile and Key Details

Q: Who are the executives of GLPG?

Mr. Michele Manto M.B.A.Chief Commercial OfficerMs. Ellen Van Der AarHead of Devel.Dr. Andre Hoekema Ph.D.Chief Bus. Officer & Member of Management BoardMs. Elizabeth GoodwinVice President of Investor RelationsMr. Dirk De NaeyerHead of Devel. OperationsMs. Alice DietrichHead of Medical AffairsMs. Sofie Van GijselHead of Investor RelationsMs. Chantal TassetHead of Devel.Marieke VermeerschHead of Corporation CommunicationMr. Bart Filius M.B.A., MBAPres, Chief Operating Officer & Member of Management BoardDr. Walid Abi-SaabChief Medical Officer & Member of Management BoardJohn MontanaManaging Director of ArgentaDr. Walid Abi-Saab M.D.Chief Medical Officer & Member of Management BoardMr. Bart Filius MBAPres, Chief Operating Officer & Chief Financial OfficerMs. Valeria CnossenGen. CounselMs. Annelies MissottenChief HR OfficerMr. Philippe AlenSenior Vice President & Head of Bus. Devel.Mr. Thad HustonChief Financial Officer & Chief Operating Officer

NASDAQ : GLPG

Galapagos NV

$33.77

-0.41-1.20%

At Close 4:00 PM

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Galapagos N.V. (GLPG) stock declined over -1.20%, trading at $33.77 on NASDAQ, down from the previous close of $34.18. The stock opened at $33.76, fluctuating between $33.41 and $34.09 in the recent session.

Stock Snapshot

34.18

Prev. Close

2.23B

Market Cap

33.41

Day Low

-4.22

P/E Ratio

-8

EPS (TTM)

-6.44

Cash Flow per Share

33.76

Open

65.9M

Number of Shares

34.09

Day High

74.65%

Free Float in %

42.35

Book Value

71.16K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 20, 2026	33.76	34.09	33.41	33.77	71.27K
Feb 19, 2026	34.33	34.40	33.74	34.18	45.04K
Feb 18, 2026	34.09	34.59	33.98	34.59	119.22K
Feb 17, 2026	33.72	34.00	33.39	33.93	151.6K
Feb 13, 2026	33.47	33.96	33.47	33.92	116.5K
Feb 12, 2026	34.01	34.13	33.42	33.43	78.16K
Feb 11, 2026	33.91	34.22	33.74	34.06	64.89K
Feb 10, 2026	33.71	34.08	33.68	33.93	46.89K
Feb 09, 2026	33.39	33.66	33.12	33.60	45.01K
Feb 06, 2026	33.38	33.60	33.17	33.36	71.19K
Feb 05, 2026	34.34	34.61	33.31	33.38	76.45K
Feb 04, 2026	34.65	34.88	34.17	34.63	109.41K
Feb 03, 2026	34.13	34.63	34.08	34.60	161.5K
Feb 02, 2026	33.60	34.35	33.53	34.23	65.5K
Jan 30, 2026	34.17	34.28	33.57	33.88	95.52K
Jan 29, 2026	34.13	34.35	33.95	34.13	57.03K
Jan 28, 2026	34.62	34.62	34.06	34.10	55.23K
Jan 27, 2026	34.65	35.06	34.61	34.64	90.87K
Jan 26, 2026	34.41	34.59	34.18	34.54	59.77K
Jan 23, 2026	34.48	34.81	34.33	34.40	105.85K

Contact Details

Mechelen, 2800

Belgium

https://www.glpg.com 321 534 2900

About Company

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.� r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Stock Peers

ARGX

-2.85-0.34%

argenx SE$844.41 REGN

-1.77-0.23%

Regeneron Pharmaceuticals, Inc.$779.67 VRTX

7.63+1.63%

Vertex Pharmaceuticals Incorporated$476.90 UTHR

-7.1-1.48%

United Therapeutics Corporation$473.42 MDGL

-1.86-0.43%

Madrigal Pharmaceuticals, Inc.$435.01 ALNY

-3.18-0.94%

Alnylam Pharmaceuticals, Inc.$336.19 PRAX

3.67+1.11%

Praxis Precision Medicines, Inc.$335.28 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

-0.87-0.33%

Krystal Biotech, Inc.$261.80 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Galapagos N.V. (NASDAQ:GLPG) closed at $33.77 USD, losing -$0.41 (-1.20%) from the previous close of $34.18. The stock is currently mid-range between its 52-week high and low $22.59 and $37.78. With a market capitalization of about $2.23 billion, Galapagos N.V. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.10). Key stats such as the average daily volume over the past year has been around 98.36 thousand shares, in line with its 52-week average. Headquartered in Mechelen, None, Galapagos N.V. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Henry Gosebruch, the company employs approximately 704 people and listed since February 27, 2012. Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need.

Technical Performance

GLPG has shown mixed momentum, gaining 1.12% over the past week and -2.98% over the past quarter, though year-to-date performance is up 2.39%. Short-term trend indicators are bearishly aligned (SMA20 -0.87%, SMA50 1.48%, SMA200 6.86%). The stock’s 14-day RSI is 49.88 (neutral), while the ATR of 0.68 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -10.61% below its high and over 49.48% above its low. Average 10-day trading volume of 96.96 thousand shares is in line with the 3-month average of 97.43 thousand, indicating normal recent market interest.

Valuation Metrics

Galapagos N.V. trades at a P/E ratio of -4.29, slightly below the S&P 500 average, with a price-to-sales ratio of 6.58 and a price-to-book ratio of 0.65 suggesting the stock is closer to book value. The P/FCF stands at -6.58, also above market averages.

Dividend & Fair Value

Galapagos N.V. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$22.82. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Galapagos N.V. generated EPS of -$7.44 over the past year. Five-year average earnings growth is -16.02%. The latest quarter delivered EPS of -$0.55. The next quarter is forecast at -$0.13. Next year's EPS is expected at -$87.48. Analyst sentiment is neutral. Analyst rating data shows there are 1 Strong Buy ratings, 0 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $40.00 to $28.00. The high target offers 18.45% upside. The low target suggests -17.09% downside. The mean target is $33.33. This offers -1.3% upside. Galapagos N.V. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by 103.56%. The prior quarter beat by 182.27%. Over the last six quarters, Apple has recorded several small beats. These include -187.5% in October 03, 2024.

Shareholding & Insider Activity

Galapagos N.V. has 65.90 million shares outstanding. The public float is 65.05 million shares, elevated short interest at 4.40% of float. This equals 1.85 million shares. The short ratio is 5.16 days. Institutional investors hold 30.68% of the float. Insiders own 25.35%.

Financial & Profitability Overview

Over the trailing twelve months, Galapagos NV generated $239.72M in revenue, or $3.64 per share. Gross margin was 99.99%, operating margin -53.35%, and net profit margin 88.31%. Returns are modest, with ROA at 4.86% and ROE at 7.57%.
On valuation metrics, Galapagos NV trades at a P/E of -4.29, P/S of 6.58 and P/B of 0.65. The current ratio is 8.63 and quick ratio is 8.56. Operationally, the company’s inventory turnover is 5.27 and cash conversion cycle is -118.18 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.00, supported by a cash flow-to-debt ratio of -30.56.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Galapagos NV posted revenue of $239.72M, down slightly from $505.28M in the prior quarter. Gross profit was $239.70M (margin 99.99%). Operating income was - $127.89M (margin -53.3%). Net income was$211.70M (EPS $3.21).
The company ended the quarter with $3.68B in cash and short-term investments, a total debt of $9.60M, and net debt of - $62.21M. Total assets were $4.36B, with equity of $2.80B. Financials further reflected weakness, with operating cash flow of - $391.21M, free cash flow of - $410.48M, and capital expenditures of - $19.27M.

Price Forecast & Outlook

Our AI price prediction model suggests that Galapagos N.V. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.3%, with price expected at $33.87 by March 06, 2026, within a range of $33.43 to $34.33 3-Month Outlook: Projected rise of 14.24%, reaching $38.58 by May 21, 2026, with a range of $36.67 to $40.69. 1-Year Outlook: Projected loss of -7.4%, with price at $31.27 by February 19, 2027, within a range of $29.44 to $33.17.

Key Takeaways

Galapagos N.V. (NASDAQ:GLPG) shares are flat 2.39% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Galapagos N.V. trading at a premium to the broader market with a P/E of -4.29. Analyst sentiment is cautious, with the majority of ratings in Sector Perform territory and a mean price target of $72.19, suggesting 113.77% upside. Our AI forecast model points to short-term strength (0.3% over two weeks), a medium-term rise (14.24% over three months), and a longer-term loss (-7.4% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Galapagos N.V. (GLPG) stock price?

Galapagos N.V. (NASDAQ: GLPG) stock price is $33.77 in the last trading session. During the trading session, GLPG stock reached the peak price of $34.09 while $33.41 was the lowest point it dropped to. The percentage change in GLPG stock occurred in the recent session was -1.2% while the dollar amount for the price change in GLPG stock was - $0.41.

GLPG's industry and sector of operation?

The NASDAQ listed GLPG is part of Biotechnology industry that operates in the broader Healthcare sector. Galapagos N.V. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of GLPG?

Mr. Michele Manto M.B.A.
Chief Commercial Officer
Ms. Ellen Van Der Aar
Head of Devel.
Dr. Andre Hoekema Ph.D.
Chief Bus. Officer & Member of Management Board
Ms. Elizabeth Goodwin
Vice President of Investor Relations
Mr. Dirk De Naeyer
Head of Devel. Operations
Ms. Alice Dietrich
Head of Medical Affairs
Ms. Sofie Van Gijsel
Head of Investor Relations
Ms. Chantal Tasset
Head of Devel.
Marieke Vermeersch
Head of Corporation Communication
Mr. Bart Filius M.B.A., MBA
Pres, Chief Operating Officer & Member of Management Board
Dr. Walid Abi-Saab
Chief Medical Officer & Member of Management Board
John Montana
Managing Director of Argenta
Dr. Walid Abi-Saab M.D.
Chief Medical Officer & Member of Management Board
Mr. Bart Filius MBA
Pres, Chief Operating Officer & Chief Financial Officer
Ms. Valeria Cnossen
Gen. Counsel
Ms. Annelies Missotten
Chief HR Officer
Mr. Philippe Alen
Senior Vice President & Head of Bus. Devel.
Mr. Thad Huston
Chief Financial Officer & Chief Operating Officer

How GLPG did perform over past 52-week?

GLPG's closing price is 49.49% higher than its 52-week low of $22.59 where as its distance from 52-week high of $37.78 is -10.61%.

How many employees does GLPG have?

Number of GLPG employees currently stands at 704.

Link for GLPG official website?

Official Website of GLPG is: https://www.glpg.com

How do I contact GLPG?

GLPG could be contacted at phone 321 534 2900 and can also be accessed through its website. GLPG operates from Generaal De Wittelaan L11 A3, Mechelen, 2800, Belgium.

How many shares of GLPG are traded daily?

GLPG stock volume for the day was 71.16K shares. The average number of GLPG shares traded daily for last 3 months was 98.36K.

What is the market cap of GLPG currently?

The market value of GLPG currently stands at $2.23B with its latest stock price at $33.77 and 65.9M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	704
Beta	0.1
Sales or Revenue	$239.72M
5Y Sales Change%	-0.344%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

GLPG Company Profile and Key Details

Galapagos NV

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Dividend & Fair Value

Valuation Metrics

Key Takeaways

Price Forecast & Outlook